Skip to content

Medicines Co., Alnylam report positive Phase 2 cholesterol med trial

March 17, 2017

—Inclisiran demonstrated significant and sustained reductions in LDL-C and high standards of safety and tolerability—

—Optimal starting dose regimen (300 mg injection administered on Day-1 and Day-90) lowered LDL-C by average of 52.6% (64 mg/dL) and up to 81% (122 mg/dL) at Day-180, and by time-adjusted mean of >50% (63 mg/dL) for the six-month period from Day-90 through Day-270; every patient displayed significant response and mean LDL-C reductions over this time period were practically constant—

—Robust ORION-1 data reaffirm inclisiran’s potential to address unmet needs with highly-differentiated, infrequent, low-volume dosing regimen of two or three injections per year—

—No material safety issues on inclisiran in ORION-1; overall incidence of adverse events for inclisiran was similar to placebo—

—The Company is actively preparing to advance inclisiran into comprehensive, global Phase III development – initially focused on United States and Europe—

—ORION-1 study presented today in Late-Breaking Clinical Trials session at American College of Cardiology’s 66th Annual Scientific Session and published in The New England Journal of Medicine—

—The Company hosted conference call at 4:30 p.m., Eastern Time, Friday, March 17–


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: